Whalesbook
March Sees Steepest Pharma Export Drop in 5 Years
India's pharmaceutical exports saw a sharp 23.17% drop in March 2026, the steepest monthly contraction in at least five years. The Ministry of Commerce and Industry reported that exports fell to $2.83 billion in March 2026 from $3.68 billion in March 2025. Industry experts believe 80-90% of this disruption was caused by logistical challenges rather than a lack of demand.
Supply Chain Snags Hit Vital Drug Shipments
The West Asia conflict severely disrupted India's pharmaceutical supply chain, which relies on Gulf transit hubs like Dubai, Abu Dhabi, and Doha for shipments to Europe, North America, and Africa. These cities are vital cold-chain transit points for temperature-sensitive products such as biologics, oncology drugs, and vaccines, where even minor refrigeration breaks or extended transit times can spoil shipments. Shipping lines imposed surcharges of $3,500-$8,000 per shipment or refused Gulf-bound cargo. Freight costs for essential active pharmaceutical ingredient (API) containers from China doubled overnight from $1,200 to $2,400 per unit. Air cargo also faced disruptions, forcing exporters to use riskier overland routes with longer transit times.
Geopolitical Risks and Cost Pressures Cloud Pharma Exports
Despite India's role as the 'Pharmacy of the World' producing 20% of global generic drugs by volume, the March downturn reveals a key vulnerability to geopolitical instability. The sector's heavy reliance on maritime corridors like the Red Sea and Strait of Hormuz, along with dependence on transit hubs, exposes it to rising costs and delivery delays. While China increasingly focuses on high-value biologics, India's strength in generics is susceptible to external shocks. Furthermore, a significant portion of India's API requirements are imported from China, creating upstream dependency. Geopolitical risks and logistical hurdles can significantly impact India's export performance, threatening contract fulfillment and profits. Prolonged disruption could raise freight and energy costs, and strain India's foreign-exchange reserves.
Long-Term Outlook Remains Strong Despite March Dip
Prior to the March dip, the Indian pharmaceutical sector showed strong resilience. For the full fiscal year 2026, overall exports reached $31.11 billion, a 2.13% increase from FY25, demonstrating steady growth despite global price pressure and trade shifts. Industry leaders expect the sector to nearly double to $130 billion by 2030, fueled by global demand and innovation. The domestic market (IPM) also saw strong growth, up 10.1% to Rs 20,012 crore in March 2026. The March export slump has not dimmed the sector's long-term positive outlook. Government schemes like Production-Linked Incentives (PLI) aim to boost API self-sufficiency and vaccine manufacturing. The industry is also moving towards higher-value segments like biologics and biosimilars to enhance global competitiveness.